CSWM
BEAM icon

Cassady Schiller Wealth Management’s Beam Therapeutics BEAM Stock Holding History

Cassady Schiller Wealth Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-84
Closed -$2.77K – 470
2024
Q1 		$2.77K Hold
84
– – ﹤0.01% 409
2023
Q4 		$2.29K Hold
84
– – ﹤0.01% 389
2023
Q3 		$2.02K Hold
84
– – ﹤0.01% 405
2023
Q2 		$2.68K Hold
84
– – ﹤0.01% 412
2023
Q1 		$2.57K Hold
84
– – ﹤0.01% 393
2022
Q4 		$3.29K Buy
+84
New +$3.76K ﹤0.01% 392

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Cassady Schiller Wealth Management's BEAM Position: Q2 2024 in Review

Cassady Schiller Wealth Management sold out of Beam Therapeutics (BEAM) in Q2 2024, closing a stake of 84 shares — an estimated $2.77K sold.

Cassady Schiller Wealth Management first reported a position in BEAM in Q4 2022 and held it in 6 quarters. The position peaked at $3.29K in Q4 2022. 214 funds tracked by Wall St. Rank hold BEAM as of Q2 2024.

  • Cassady Schiller Wealth Management reported no remaining Beam Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Cassady Schiller Wealth Management sold 84 Beam Therapeutics shares in Q2 2024, an estimated $2.77K.
  • Cassady Schiller Wealth Management first reported a position in Beam Therapeutics in Q4 2022 and held it in 6 quarters.
  • Cassady Schiller Wealth Management's Beam Therapeutics position peaked at $3.29K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2024.

Based on Cassady Schiller Wealth Management's 13F filing for Q2 2024, filed 12 Aug 2024.